Saturday 17 October 2026
Export KZIA’s income statement to Excel — free account
Novogen Limited
KZIA Healthcare Biotechnology
Novogen Limited’s revenue for fiscal 2025 (year ended June 2025) was $1.2 million, down 24.7% from fiscal 2024.
7.25
0.15
−2.03%
Follow KZIA
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.22 | 0.19 | 0.32 | 2.86 | |
Current Ratio |
0.24 | 0.21 | 0.35 | 2.87 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
2.94% | 0.79% | 6.52% | 0.14% | |
Debt/Equity |
(0.06) | (0.04) | (0.05) | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Intangible Assets out of Total Assets |
0.71 | 0.81 | 0.18 | 0.02 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(6.28) | (5.49) | (8.60) | (6.26) | |
Working Capital |
(12.89) | (8.54) | (5.91) | 29.94 | |
Capital Expenditures |
0.00 | — | 0.00 | — | |
Net Current Asset Value |
(16.69) | (11.93) | (6.11) | 29.76 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
1.31 | 0.27 | 1.34 | 1.32 | |
Average Payables |
6.30 | 4.44 | 4.73 | 5.12 | |
Average Assets |
19.76 | 14.99 | 11.42 | 31.28 | |
Average Common Equity |
3.48 | 2.57 | 1.37 | 16.97 |
Columns are period end dates · fundamentals updated 2 Oct 2026